UroGen Pharma Ltd. (URGN)
Market Cap | 622.71M |
Revenue (ttm) | 84.30M |
Net Income (ttm) | -104.32M |
Shares Out | 41.13M |
EPS (ttm) | -3.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 539,955 |
Open | 16.42 |
Previous Close | 16.48 |
Day's Range | 15.06 - 16.42 |
52-Week Range | 8.69 - 24.13 |
Beta | 1.09 |
Analysts | Strong Buy |
Price Target | 42.88 (+183.22%) |
Earnings Date | Aug 8, 2024 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris... [Read more]
Financial Performance
In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $42.88, which is an increase of 183.22% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/7/d/press1-2483572.jpg)
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/2/b/press1-2483162.jpg)
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
![](https://cdn.snapi.dev/images/v1/e/p/press2-2478082.jpg)
Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions
SAN FRANCISCO & BELLEVUE, Wash.--(BUSINESS WIRE)--Today, Uber's advertising division announced an exclusive partnership with T-Mobile Advertising Solutions and its rideshare media network – Octopus In...
![](https://cdn.snapi.dev/images/v1/m/d/press14-2478072.jpg)
AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100
BERWYN, Pa.--(BUSINESS WIRE)--Bill Oldham, chairman and president, AscellaHealth, honored as a 2024 Philadelphia Titan 100.
![](https://cdn.snapi.dev/images/v1/v/c/press11-2478071.jpg)
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...
![](https://cdn.snapi.dev/images/v1/4/4/press15-2468035.jpg)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/a/q/press5-2465894.jpg)
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today sh...
![](https://cdn.snapi.dev/images/v1/u/t/conf6-2463412.jpg)
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/b/2/press15-2458752.jpg)
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...
![](https://cdn.snapi.dev/images/v1/v/q/conf15-2443241.jpg)
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/n/h/conf8-2426764.jpg)
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/v/m/conf17-2414498.jpg)
UroGen Pharma to Participate at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/f/6/press12-2411043.jpg)
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi...
![](https://cdn.snapi.dev/images/v1/y/j/press15-2410718.jpg)
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda...
![](https://cdn.snapi.dev/images/v1/r/f/press10-2410649.jpg)
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi...
![](https://cdn.snapi.dev/images/v1/w/z/conf14-2408896.jpg)
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/g/s/press6-2376433.jpg)
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/8/k/press8-2371259.jpg)
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...
![](https://cdn.snapi.dev/images/v1/p/m/press4-2354068.jpg)
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...
![](https://cdn.snapi.dev/images/v1/g/a/press6-2324157.jpg)
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/7/q/conf17-2306264.jpg)
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/q/e/conf11-2293308.jpg)
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...
![](https://cdn.snapi.dev/images/v1/m/f/press6-2242200.jpg)
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an...
![](https://cdn.snapi.dev/images/v1/3/x/press14-2232372.jpg)
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers.
![](https://cdn.snapi.dev/images/v1/f/j/press7-2225546.jpg)
UroGen Pharma to Participate in the B. Riley Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...